By Marjan Bejan
Antimicrobial resistance represents one of the most urgent threats to global health, directly causing 1.14 million deaths in 2021, with future projections showing no sign of slowing. This phenomenon is driven by antibiotic misuse and overuse in various sectors, including agriculture and slow pharmaceutical innovations. Antimicrobial resistance manifests when microorganisms undergo evolutionary processes that lead to mutations and thus resistance against antimicrobial medications. As highlighted in The Drugs Don’t Work, by Dame Sally Davies et al, we are entering a post-antibiotic era in which routine infections and minor surgeries can once again become life-threatening. Antimicrobial peptides (AMPs) are naturally occurring molecules that are a fundamental component of innate immunity in multicellular organisms. They exhibit broad-spectrum activity, with the ability to directly kill bacteria, viruses and even cancer cells. Thus, antimicrobial peptides constitute one of the most promising alternatives to antibiotics, functioning as innate immune-derived therapeutics within the body’s first line of defence. Many of these antimicrobial peptides work by destroying intracellular functions, disrupting metabolism and protein synthesis. They also employ a membrane-lytic mechanism that reduces mutational escape, whereby antimicrobial peptides interact with the negatively charged bacterial membranes. This leads to cell membrane lysis due to the formation of pores that cause ion efflux, and consequently, the release of cellular content. Hence, it is this multifaceted mode of action, where cell membranes and intracellular pathways are targeted, that makes them particularly promising against drug resistant pathogens. Furthermore, studies have shown that antimicrobial peptides can act synergistically with conventional antibiotics, enabling combination therapies that kill drug-resistant bacteria, prevent further resistance, and enhance overall therapeutic efficacy. Laboratory studies, including work on peptides such as pexiganan and LL-37, have demonstrated potent activity against multidrug-resistant bacteria, highlighting their promise as next-generation therapeutics. However, a translation gap persists between in-vitro efficacy and in-vivo performance, as enzymatic degradation, short half-life, and limited tissue penetration can restrict clinical effectiveness. Despite these challenges, it is this multifaceted mode of action that makes AMPs particularly promising against drug-resistant pathogens. Despite their promising nature, antimicrobial peptides have several barriers that currently limit widespread clinical use. These include both pharmacological and economic issues, including being unstable in biological environments, potential toxicity, and high production costs, all factors that inhibit the replacement of conventional antibiotics with AMPs. Toxicity in the use of antimicrobial peptides is a major obstacle in their clinical use. This is because AMPs can harm human cells at high concentrations, narrowing the therapeutic window, as well as the difficulty of achieving selective toxicity, where toxicity is sufficient in killing bacteria without damaging human cells. Therefore, this causes issues between toxicity and therapeutic index. Another major factor that limits mass production is the cost of producing AMPs. This limits mass production and scalability, due to the high cost of natural peptide synthesis, with prices ranging from $50 to $600 per gram. Thus, cost efficiency and scalability remain major hurdles in generalising their use. However, in relation to these challenges, recent research has focused on innovative strategies to overcome the toxic nature and enhance the cost-effectiveness of antimicrobial peptides. One approach that can be used to minimise damage to cells is through the use of nanoparticles. Using non-reactive metals such as gold and silver can reduce toxicity and improve targeted delivery. Furthermore, hybrid peptides made using both antibiotics and antimicrobial peptides are proving to be more successful due to producing a synergetic effect, reducing the dosage of each component, and overcoming the issue of resistance. Antimicrobial peptides demonstrate immense potential as next-generation therapeutics, yet several pharmacological and economic barriers currently prevent their widespread clinical application. Issues of toxicity, instability in biological environments, and high production costs limit both scalability and therapeutic safety, creating a delicate balance between efficacy and selectivity. However, emerging innovations, such as nanoparticle-enhanced bioavailability and combination therapy, offer promising solutions to these drawbacks. Ultimately, antimicrobial peptides are likely to serve as an adjunct rather than a wholesale replacement strategy for conventional antibiotics, complementing existing therapies and reinforcing our ability to combat antimicrobial resistance.
0 Comments